Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of obesity. It is expected to grow at a CAGR of 11.6% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.

Key Takeaways

• It is reported that the obesity prevalence rate in the Asia Pacific region is increasing rapidly. This surge in obesity rates is expected to augment the need for effective weight management solutions including anti-obesity drugs.
• In January 2024, it was reported that Chinese biotechnology company Innovent Biologics Inc. and Eli Lilly and Company’s anti-obesity drug mazdutide achieved positive Phase III results, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the Asia Pacific anti-obesity drugs market value.
• One of the major market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai, the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China.

Asia Pacific Anti-Obesity Drugs Market Analysis

Anti-obesity drugs comprise medications that aid in reducing or controlling the weight of an individual such as appetite suppressants, fat absorption inhibitors, and metabolic enhancers. The rising public awareness regarding the risks associated with obesity like cardiovascular diseases, hypertension, and diabetes, is prompting obese patients to seek appropriate treatments including weight loss drugs. Further, increased initiatives from the government to combat obesity are expected to drive the Asia Pacific anti-obesity drugs market growth.

The high prevalence of obesity directly influences the market demand for anti-obesity drugs. It is reported that the obesity prevalence rate in the Asia Pacific region is growing rapidly. In China, over 50% of adults and nearly 20% of school-age children are experiencing overweight conditions . This surge in obesity rates can be attributed to changing dietary habits and increased sedentary lifestyles, which is expected to augment the need for effective weight management solutions, thereby boosting the market share of anti-obesity drugs.

One of the major Asia Pacific anti-obesity drugs market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, a Chinese biopharmaceutical company Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai (a biosimilar to semaglutide), the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China. The increased access to a wide range of anti-obesity drugs in the region is anticipated to propel the market growth.

The Asia Pacific anti-obesity drugs market share is positively influenced by the ongoing research in obesity treatment solutions which is leading to the introduction of novel anti-obesity drugs. In January 2024, it was reported that Innovent Biologics Inc. (a Chinese biotechnology company) and Eli Lilly and Company’s anti-obesity drug mazdutide (a dual glucagon-like peptide-1 (GLP-1) glucagon receptor agonist) achieved positive Phase III results. In the GLORY-1 trial, the drug met both of its primary endpoints, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the market value.

Asia Pacific Anti-Obesity Drugs Market Segmentation

Market Breakup by Drugs

• Semaglutide
• Phentermine/Topiramate
• Naltrexone/Bupropion
• Liraglutide
• Gelesis 100
• Orlistat
• Phentermine
• Methamphetamine
• Tirzepatide

Market Breakup by Drug Class

• Amphetamine
• GLP-1 Receptor Agonist
• Lipase Inhibitor

Market Breakup by Mechanism of Action

• Centrally Acting Drugs
• Peripherally Acting Drugs

Market Breakup by Route of Administration

• Oral
• Subcutaneous

Market Breakup by Prescription Type

• Prescription Drugs
• Over The Counter Drugs

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Drug Store and Retail Pharmacies
• Online Pharmacies

Market Breakup by Region

• China
• Japan
• ASEAN
• Australia
• India
• Other

Asia Pacific Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• VIVUS Inc.
• Pfizer, Inc.
• Novo Nordisk
• Bayer AG
• F Hoffmann-La Roche
• Glaxosmithkline
• Arena Pharmaceuticals
• Eisai Co. Ltd
• Takeda Pharmaceutical Company
• Nalpropion Pharmaceuticals Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Asia Pacific anti-obesity drugs market forecast outlook for 2024-2032?
The Asia Pacific anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.70% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.

What are the major factors aiding the Asia Pacific anti-obesity drugs market demand?
The rising obesity rates and increased initiatives from the government are fuelling the demand for the market.

What are the major Asia Pacific anti-obesity drugs market trends?
One of the significant trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai, the first biosimilar drug expected to provide competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China.

What is the market segmentation based on the drugs?
Based on the drugs, the market is segmented into semaglutide, phentermine/topiramate, naltrexone/bupropion, liraglutide, gelesis 100, orlistat, phentermine, methamphetamine, and tirzepatide.

What are the various drug classes available in the market?
Drug classes available in the market include amphetamine, GLP-1 receptor agonist, and lipase inhibitors.

What is the market breakup by mechanism of action?
By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.

What is the market segmentation based on the route of administration?
The market breakup by route of administration includes oral and subcutaneous.

What is the market segmentation based on the prescription type?
The market breakup by prescription type includes prescription drugs and over the counter drugs.

What are the major distribution channels of anti-obesity drugs?
Distribution channels of the market are hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

What is the market segmentation by countries?
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.

Who are the key players involved in the Asia Pacific anti-obesity drugs market?
The key players in the market are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F. Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc.


This product will be delivered within 5-7 business days.